LeMaitre Vascular, Inc. (NASDAQ:LMAT) Shares Bought by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 4.1% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 11,539 shares of the medical instruments supplier’s stock after purchasing an additional 454 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. owned approximately 0.05% of LeMaitre Vascular worth $1,063,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. New York State Teachers Retirement System increased its stake in LeMaitre Vascular by 1.2% during the 4th quarter. New York State Teachers Retirement System now owns 8,189 shares of the medical instruments supplier’s stock valued at $755,000 after buying an additional 100 shares during the period. Flputnam Investment Management Co. raised its holdings in LeMaitre Vascular by 3.6% during the fourth quarter. Flputnam Investment Management Co. now owns 2,923 shares of the medical instruments supplier’s stock worth $269,000 after purchasing an additional 102 shares in the last quarter. Norden Group LLC lifted its position in LeMaitre Vascular by 4.5% in the fourth quarter. Norden Group LLC now owns 2,371 shares of the medical instruments supplier’s stock worth $218,000 after purchasing an additional 103 shares during the period. Blue Barn Wealth LLC boosted its stake in LeMaitre Vascular by 4.4% during the 4th quarter. Blue Barn Wealth LLC now owns 2,485 shares of the medical instruments supplier’s stock valued at $229,000 after purchasing an additional 104 shares in the last quarter. Finally, Shaker Investments LLC OH increased its position in shares of LeMaitre Vascular by 0.8% during the 4th quarter. Shaker Investments LLC OH now owns 13,948 shares of the medical instruments supplier’s stock valued at $1,285,000 after purchasing an additional 112 shares during the period. 84.64% of the stock is owned by institutional investors and hedge funds.

LeMaitre Vascular Price Performance

NASDAQ LMAT opened at $81.40 on Monday. The firm has a market capitalization of $1.84 billion, a price-to-earnings ratio of 44.48, a price-to-earnings-growth ratio of 2.22 and a beta of 0.86. The company has a 50 day simple moving average of $84.19 and a 200-day simple moving average of $92.41. LeMaitre Vascular, Inc. has a 52-week low of $71.42 and a 52-week high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings data on Thursday, May 1st. The medical instruments supplier reported $0.48 earnings per share for the quarter, missing the consensus estimate of $0.50 by ($0.02). The company had revenue of $59.87 million during the quarter, compared to analyst estimates of $57.61 million. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The firm’s quarterly revenue was up 12.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.44 EPS. On average, analysts predict that LeMaitre Vascular, Inc. will post 1.94 EPS for the current year.

LeMaitre Vascular Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, May 29th. Investors of record on Thursday, May 15th will be given a dividend of $0.20 per share. The ex-dividend date of this dividend is Thursday, May 15th. This represents a $0.80 dividend on an annualized basis and a yield of 0.98%. LeMaitre Vascular’s payout ratio is 40.40%.

Analyst Ratings Changes

Several analysts have recently weighed in on the company. Wells Fargo & Company initiated coverage on LeMaitre Vascular in a report on Thursday, February 13th. They issued an “equal weight” rating and a $95.00 price objective for the company. Oppenheimer lowered shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research report on Friday, February 28th. Barrington Research downgraded shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a report on Friday, February 28th. Finally, Lake Street Capital increased their target price on shares of LeMaitre Vascular from $105.00 to $110.00 and gave the company a “buy” rating in a research note on Friday, February 28th. Five analysts have rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $98.14.

Insider Buying and Selling at LeMaitre Vascular

In related news, CEO George W. Lemaitre sold 76,868 shares of the stock in a transaction that occurred on Monday, May 19th. The stock was sold at an average price of $85.79, for a total value of $6,594,505.72. Following the transaction, the chief executive officer now owns 1,796,783 shares in the company, valued at approximately $154,146,013.57. This represents a 4.10% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Trent G. Kamke sold 2,009 shares of the firm’s stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $82.12, for a total transaction of $164,979.08. Following the transaction, the insider now directly owns 5,564 shares in the company, valued at approximately $456,915.68. The trade was a 26.53% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 102,009 shares of company stock worth $8,721,836 over the last 90 days. 9.50% of the stock is currently owned by corporate insiders.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.